Essential Pharma acquires Renaissance Pharma Ltd
Essential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.<br /><br />
Unitaid awards Medincell US$6m to fight malaria
Global health agency Unitaid has awarded French Medincell Corp (Jacou) an extension grant of up to US$ 6 million over three years to fund thesatety testing of its malaria vaccine […]
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline […]
TME Pharma gets FDA Fast Track for Glioblastoma
TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma's CXCL12 inhibitor, in combination with radiotherapy and bevacizumab […]
Forbion participates in US financing rounds
Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located […]
New law to speed up clinical trials
With a new law, the German government wants to increase the number of clinical trials conducted in Germany and make the country number one in Europe again.
Gut bacteria seed autoimmunity-inducers
A bacterium of the gut microbiome seems to spark an autoimmune disease in the kidneys by leaking antigens that trigger the immune system.
Innocent Meat bags €3m financing
Cultivated meat producer Innocent Meat GmbH has cashed in €3m in funding from Venture Capital Fonds MV and an anonymous business angel.
Spanish Ferrer SA pays €122.5m for ALS candidate
Spanish Ferrer Internacional, SA has aquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialise the oral Phase I experimental ALS treatment.
Novo Nordisk to acquire Cardior Pharmaceuticals
Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.